key: cord-0795960-qw56lfr9 authors: van Laar, Sylvia A.; de Boer, Mark G. J.; Gombert‐Handoko, Kim B.; Guchelaar, Henk‐Jan; Zwaveling, Juliette title: Liver and kidney function in patients with Covid‐19 treated with remdesivir date: 2021-05-04 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14831 sha: 7dd249aa5abebd36990fef25ead50c639095a378 doc_id: 795960 cord_uid: qw56lfr9 For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid‐19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m(2). Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid‐19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results. For the treatment of Covid-19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid-19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m 2 . Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results. 1, 7, 8 These impaired functions were included as contraindications for treatment in the summary of product characteristics. 1, 9 We report changes in renal and liver functions during treatment with remdesivir in a Covid-19 patient population, regardless of the initial laboratory values. Hereby, additional information was obtained about the incidence and severity of nephro-and hepatotoxicity due to remdesivir treatment in clinical practice. In total, 103 patients were included in this study, of whom at least 1 of the laboratory measurements was available, the majority of them being male (68%), and the median (interquartile range, IQR) age was 64 (56-75) years (Table 1 ). • Patients with an impaired kidney or liver function were excluded from the trials. • Impaired kidney or liver function are stated as contraindication for treatment with remdesivir. • This real-world population of patients with Covid-19 includes 20% of patients potentially excluded from clinical trials based on their renal or liver function. • Hepatoxicity and nephrotoxicity of remdesivir are mostly mild, and severe adverse events are limited. should not be absolute if functions are monitored regularly. It is important to emphasize that remdesivir is not the only independent factor that could cause nephrotoxicity or hepatotoxicity in these patients. Both Covid-related and non-Covid related risk factors are known, of which age of 65 years and older is 1. 10, 11 However, in our patients, age was not identified as an independent risk factor for nephro-or hepatotoxicity. Remdesivir is extensively metabolized; for the prodrug and its metabolites, respectively, no and modest (<2-fold) accumulation was observed after multiple dosing of 150 mg for 14 days. 12 Also, comparable clearance was shown between a patient with an impaired and a patient with normal kidney function. 13 Therefore, although remdesivir metabolites are mostly renally excreted, we do not expect that poor renal function will cause clinically relevant blood level elevation within 5 days of treatment resulting in increased toxicity or efficacy. In a real-world population, we found that the incidence of decreased eGFR during treatment with remdesivir was comparable to the RCTs and was at most moderate. Furthermore, we reported a higher incidence of patients with non-severe transaminase elevation. However, with only 2 patients with a reversible severe adverse event, this was not more than in RCTs. Patients meeting contraindications seem not to develop more nephro-or hepatotoxicity on remdesivir treatment. Therefore, there may be no reason for these contraindications to be absolute. However, monitoring remains necessary. In case of a further decline of organ functions during treatment with remdesivir, we believe it is the role of the clinician to assess the origin of the impairment. Our observations indicate that kidney and liver dysfunction should not be an absolute contraindication for the use of remdesivir in Covid-19 patients, and that by regularly monitoring kidney and liver function, treatment with remdesivir can be justified in these patients. Verification of these findings in a larger cohort is needed. This research received no specific grand from any funding agency in public, commercial or not-for-profit sectors. There are no competing interests to declare. The data that support the findings of this study are available from the corresponding author upon reasonable request. ORCID Sylvia A. van Laar https://orcid.org/0000-0002-0941-2103 Remdesivir for the Treatment of Covid-19 -Final Report Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19 A Valid Warning or Clinical Lore: An Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities Evaluation of sulfobutyletherbeta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy Controlled Trial of Ebola Virus Disease Therapeutics Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Gilead Sciences. 2020. Summary of Product Characteristics: Veklury (remdesivir) COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup Acute Kidney Injury: Diagnosis and Management Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity LUMC-Covid-19 research group. Liver and kidney function in patients with Covid-19 treated with remdesivir